CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
January 03, 2018
January deadline approaches for Quality of Life CommitteePublished: January 03, 2018Category: Group updates  The Quality of Life committee is currently seeking 2-3 individuals with enthusiastic interest in the measurement of patient-reported outcomes in clinical trials. Read More |
CCTG network investigators recognized with the Order of CanadaPublished: January 03, 2018Category: News  CCTG network researchers have been recognized by Governor General Julie Payette who announced the Order of Canada appointments on Friday, Dec. 29. Please join us in congratulating Dr. Pritchard, Dr. Gleave and Dr. Eisenhauer on this wonderful honour and for their outstanding contributions to cancer clinical trial research in Canada. Read more. Read More |
December 20, 2017
|
IND.234 - Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol has been centrally activated with participation limited to invited centres. Read More |
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
Read More |
|
|
December 07, 2017
|
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor. |
|
|
November 15, 2017
 OVC.1 (NRG GY004) A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer has been closed to accrual as of Nov 10, 2017.
|